Thomas Melzer spoke about the impact that the recent financial downturn has had on venture capital investment, specifically addressing bioscience investments.

Synthetic genomics is a new field that engages in the design and assembly of genes and chromosomes from chemically synthesized oligonucleotides to create cells with properties unobtainable by conventional molecular biology ...